SCHEMBL20090080

SCHEMBL20090080

S=P(c1ccccc1)(c1ccccc1)c1ccc2cc(-c3ccc4c5c6ccccc6ccc5c5nc6ccccc6n5c4c3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.42
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 4/20 0.42
KMT2A Q03164 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 5/20 0.39
MEN1 O00255 3/20 0.39
CAMKK1 Q8N5S9 2/20 0.39
CAMKK2 Q96RR4 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CASP1 P29466 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASP7 P55210 1/20 0.39
POLB P06746 2/20 0.38
BCL2 P10415 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20090085 0.97 HPGD (0.40) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960321 0.95 HPGD (0.35) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960331 0.94 ALDH1A1 (0.34) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL20090125 0.93 HPGD (0.38) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960238 0.93 MAPT (0.44) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL20090101 0.92 HPGD (0.44) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960339 0.92 ALDH1A1 (0.34) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL20096538 0.91 BCL2 (0.38) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL19965997 0.90 ALDH1A1 (0.35) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL20090116 0.90 HPGD (0.36) HPGDKDM4EALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2019-07-16 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME CRY1, CRY2, PER2 HPGD 2982/4885KDM4E 1997/4885ALDH1A1 750/4885
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, PER2 HPGD 2982/4885KDM4E 1997/4885ALDH1A1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.